HIGHLIGHTS
- who: Ilias B. Esmagambetov and collaborators from the Stanford University, United States have published the research work: rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19, in the Journal: (JOURNAL) of March/11,/2020
- what: In current work the authors developed a recombinant adeno-associated viral_vector (rAAV), expressing a SARS-CoV-2 spike receptor-binding domain (RBD)specific antibody P2C5 fused with a human IgG1 Fc fragment (P2C5-Fc) using methods of molecular biotechnology and bioprocessing. The authors evaluated not only animal survival and body weight decrease but also examined . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.